Bala Pushparaji1,2, Teodora Donisan3, Dinu V Balanescu3, Nicolas Palaskas1, Peter Kim1, Juan Lopez-Mattei1, Mehmet Cilingiroglu1,4, Saamir A Hassan1, Konstantinos Dean Boudoulas5, Konstantinos Marmagkiolis1,6, Ludhmila Abrahao Hajjar7, Cezar A Iliescu8. 1. Department of Cardiology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1451, Houston, TX, 77030, USA. 2. Department of Internal Medicine, Maimonides Medical Center, Brooklyn, NY, USA. 3. Department of Internal Medicine, Beaumont Hospital, Royal Oak, MI, USA. 4. School of Medicine, Bahcesehir University, Istanbul, Turkey. 5. The Ohio State University Wexner Medical Center, Columbus, OH, USA. 6. HCA Northside Hospital, St. Petersburg, FL, USA. 7. Instituto Do Coração, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil. 8. Department of Cardiology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Unit 1451, Houston, TX, 77030, USA. ciliescu@mdanderson.org.
Abstract
PURPOSE OF REVIEW: To highlight the range of illnesses and procedures that the interventional onco-cardiologists face in their daily practice, along with the recent additions to anti-cancer therapies and their related cardiotoxicity. RECENT FINDINGS: Immune checkpoint inhibitors (ICI) are not devoid of cardiotoxicity as thought earlier and lead to an increased incidence of myocarditis. Transcatheter valve replacement has been shown to be a safer alternative to surgical replacement in cancer patients. Interventional onco-cardiology is a novel field that addresses cardiovascular diseases in the setting of cancer. Traditionally excluding cancer patients from clinical trials has led to a dearth of information needed to tackle cardiac conditions like Takotsubo cardiomyopathy, malignant pericardial effusions, and radiation-induced vascular diseases encountered either exclusively or predominantly in this high-risk population. This review discusses the various treatment options available in the interventional armamentarium with a particular focus on ICI-myocarditis and transcatheter aortic valve replacement in cancer patients.
PURPOSE OF REVIEW: To highlight the range of illnesses and procedures that the interventional onco-cardiologists face in their daily practice, along with the recent additions to anti-cancer therapies and their related cardiotoxicity. RECENT FINDINGS: Immune checkpoint inhibitors (ICI) are not devoid of cardiotoxicity as thought earlier and lead to an increased incidence of myocarditis. Transcatheter valve replacement has been shown to be a safer alternative to surgical replacement in cancer patients. Interventional onco-cardiology is a novel field that addresses cardiovascular diseases in the setting of cancer. Traditionally excluding cancer patients from clinical trials has led to a dearth of information needed to tackle cardiac conditions like Takotsubo cardiomyopathy, malignant pericardial effusions, and radiation-induced vascular diseases encountered either exclusively or predominantly in this high-risk population. This review discusses the various treatment options available in the interventional armamentarium with a particular focus on ICI-myocarditis and transcatheter aortic valve replacement in cancer patients.
Authors: Sarah C Darby; Marianne Ewertz; Paul McGale; Anna M Bennet; Ulla Blom-Goldman; Dorthe Brønnum; Candace Correa; David Cutter; Giovanna Gagliardi; Bruna Gigante; Maj-Britt Jensen; Andrew Nisbet; Richard Peto; Kazem Rahimi; Carolyn Taylor; Per Hall Journal: N Engl J Med Date: 2013-03-14 Impact factor: 91.245
Authors: Jeanette F Winther; Smita Bhatia; Luise Cederkvist; Thorgerdur Gudmundsdottir; Laura Madanat-Harjuoja; Laufey Tryggvadottir; Finn Wesenberg; Henrik Hasle; Anna Sällfors Holmqvist Journal: Cancer Date: 2018-10-11 Impact factor: 6.860
Authors: Jorge E Cortes; Hagop Kantarjian; Neil P Shah; Dale Bixby; Michael J Mauro; Ian Flinn; Thomas O'Hare; Simin Hu; Narayana I Narasimhan; Victor M Rivera; Tim Clackson; Christopher D Turner; Frank G Haluska; Brian J Druker; Michael W N Deininger; Moshe Talpaz Journal: N Engl J Med Date: 2012-11-29 Impact factor: 91.245